Ocular Therapeutix Modernizes Brand to Emphasize Retina Health
In a significant move aimed at aligning its identity with its mission, Ocular Therapeutix, Inc. (NASDAQ: OCUL) has launched an innovative corporate branding initiative along with a new website. This transition marks a pivotal shift towards a dedicated focus on retinal health, showcasing the company’s commitment to redefining the experience of patients dealing with retinal diseases.
A Fresh Logo and Website Design
Ocular's new logo is crafted with visual accessibility in mind, echoing the scientific and transformative essence of the organization. The circular design of the “O” symbolizes the eye and its intricate relationship with the retina, complemented by a vibrant full-spectrum color palette that mirrors the dynamic nature of human vision.
Leadership's Vision on Retinal Diseases
“Retinal disease, particularly wet age-related macular degeneration (AMD), stands as a leading cause of vision loss, significantly impacting the lives of millions,” expressed Dr. Pravin U. Dugel, Executive Chairman, President, and CEO of Ocular Therapeutix. He emphasized that the new branding isn't just cosmetic; it reflects the substantial progress achieved through the company’s ongoing SOL trials and its unwavering commitment to patient care and innovation.
Addressing Treatment Challenges
Retinal diseases present unique challenges due to the complex nature and demanding treatment procedures involved. Currently, patients with wet AMD often face the burden of up to 12 injections each year, making adherence to treatment a daunting task. This high frequency can lead to treatment discontinuation and consequently, unfavorable long-term outcomes.
Despite these challenges, Ocular Therapeutix is at the forefront of developing new solutions aimed at improving the quality of life for these patients. The investigational therapy known as AXPAXLI™ (or OTX-TKI) is a novel axitinib hydrogel administered through intravitreal injection. This innovative treatment holds promise for enhancing durability and improving long-term vision outcomes for individuals affected by wet AMD and various other retinal conditions.
Showcasing Innovations in Retinal Health
The company’s commitment to revolutionizing retinal health will be further showcased as this new branding makes its public debut at the next conference of the American Society of Retina Specialists (ASRS). This event is set to highlight Ocular's innovative approach within the field of retinal disease treatment.
Continuing the Journey
Now live on the company’s new website and across its social media platforms, the updated brand identity reflects Ocular Therapeutix’s strategic direction. This rebranding illustrates a deeper engagement with the community and a pledge to transformational treatments for retinal diseases.
Ocular Therapeutix, Inc. remains steadfast on its mission of enhancing the patient journey. Its lead investigational therapy, AXPAXLI, is currently advancing through Phase 3 clinical trials, impactful to those suffering from wet AMD.
Exploring Ocular's Advancements
In addition to AXPAXLI, Ocular Therapeutix is leveraging its proprietary ELUTYX™ technology for other products as well. The FDA-approved DEXTENZA® serves as a corticosteroid treatment for ocular inflammation and pain post-surgery, alongside its investigational candidate OTX-TIC for open-angle glaucoma. These innovative products showcase Ocular's dedication to improving patient care across the spectrum of eye health.
Connecting with Stakeholders
As the biopharmaceutical landscape evolves, Ocular Therapeutix stands out as a pioneer by efficiently navigating the complexities of retinal disease treatment. Stakeholders and patients are invited to follow the company’s advancements through its website and social media channels, ensuring they remain informed of the latest developments in retinal health.
For further inquiries, contact:
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com
Frequently Asked Questions
What is the main goal of Ocular Therapeutix's rebranding?
The rebranding aims to emphasize Ocular Therapeutix's commitment to transforming the treatment landscape for retinal diseases, particularly targeting conditions like wet AMD.
What is AXPAXLI and how does it work?
AXPAXLI is an investigational therapy that utilizes an axitinib hydrogel delivered via intravitreal injection, designed to enhance patient outcomes in treating wet AMD.
How does the logo reflect the company's mission?
The logo symbolizes the human eye and retina, utilizing a vibrant color scheme to represent the essence of sight and life, aligning with Ocular's vision of enhancing retinal health.
Where will the new branding be showcased?
The new corporate branding will debut at the upcoming American Society of Retina Specialists (ASRS) conference, highlighting Ocular's innovative efforts in retinal treatment.
Who can I contact for investor relations inquiries?
For investor relations inquiries, Bill Slattery, Vice President of Investor Relations, can be reached at bslattery@ocutx.com.
